With a long track record in life science dating back to 1995, Aravis partners have been lead investors in some of the first wave Swiss life science companies such as Modex, Genedata, Cytos, Glycart, Esbatech and Novimmune. This track record of successful active early involvement in Swiss companies is continuing with lead investments in for example Evolva, Symetis, TelorMedix and Biotie (formely Synosia).
Aravis's team of sector specialists have a distinctive expertise in assessing scientific risks, besides other risks, allowing for the selection of pre-proof of concept (i.e. platform technologies, late pre-clinical and early clinical) companies and turnaround situations offering outstanding risk-return profiles. Our long track record in keeping companies solidly financed through difficult cycles and our expertise in capital markets and creativity to find routes to liquidity have been a major success factor for most of our companies.
Since 2001, investment interests have also focused on cross-border deals, for example the relocation of Evolva from Copenhagen to the Basel Area or the foundation of Telormedix in Lugano from technology spun out of the University of California San Diego.
Aravis also has a particular interest and competence in companies working with highly disruptive technology platforms and in the broader area of Immunology.
In all these transactions, Aravis strives to lead and structure the financing rounds. Taking active and senior board positions we support our portfolio companies with our human, industrial, financial and capital markets global networks.
Aravis has built up strong ties with the VC community elsewhere in Continental Europe, Asia and the West Coast of the USA and has been able to build strong financing syndicates with funds in each of these locations.
This worldwide network of partners opens doors in a number of geographic locations. In particular, the long standing cooperation with 5AM Ventures in Menlo Park, California, or with the Economic Development Board of Singapore puts Aravis in a unique position to syndicate broad international deals.